79169641 - X CHIOME

Information

• Trademark
• 79169641

• Source

• Serial Number

  79169641

• Registration Number

  5126156

• International Classifications

  • 5 - Pharmaceutical and veterinary preparations
  • 42 - Scientific and technological services and research and design relating thereto

• Filing Date

  April 28, 2015
  9 years ago

• Registration Date

  January 24, 2017
  7 years ago

• Transaction Date

  November 12, 2023
  a year ago

• Status Date

  February 06, 2023
  a year ago

• Published for Opposition Date

  November 08, 2016
  8 years ago

• Location Date

  February 06, 2023
  a year ago

• Status Code

  706

• Current Location

  GENERIC WEB UPDATE

  Employee Name

  MAHONEY, PAULA M

• Attorney Docket Number

  T66872

  Attorney Name

  Jeffrey H. Handelsman

  Law Office Assigned Location Code

  N10

• Owners

  • CHIOME BIOSCIENCE INC.

Case File Statements

• DM0000: The mark consists of a stylized "X" in white, within a blue square. Centered below the "X" is the term "CHIOME" in blue.
• GS0051: Monoclonal antibodies for medical [ or veterinary ] purposes, namely, for oncological, viral, infectious, endocrine, metabolic, neurological, cardiovascular, hematological, cardiopulmonary, respiratory, musculoskeletal, renal, hepatological, gastrointestinal, genitourinary, ophthalmic, dermatological, and immune system related diseases and disorders; peptides and proteins for medical [ or veterinary ] purposes, namely, for oncological, viral, infectious, endocrine, metabolic, neurological, cardiovascular, hematological, cardiopulmonary, respiratory, musculoskeletal, renal, hepatological, gastrointestinal, genitourinary, ophthalmic, dermatological, and immune system related diseases and disorders; [ biological and chemical preparations and reagents for medical or veterinary purposes, namely, for oncological, viral, infectious, endocrine, metabolic, neurological, cardiovascular, hematological, cardiopulmonary, respiratory, musculoskeletal, renal, hepatological, gastrointestinal, genitourinary, ophthalmic, dermatological, and immune system related diseases and disorders; ] medicines for human purposes, namely, for oncological, viral, infectious, endocrine, metabolic, neurological, cardiovascular, hematological, cardiopulmonary, respiratory, musculoskeletal, renal, hepatological, gastrointestinal, genitourinary, ophthalmic, dermatological, and immune system related diseases and disorders [ ; medicines for dental purposes, namely, for infectious diseases, neurological diseases or inflammatory diseases; medicines for veterinary purposes, namely, for oncological, viral, infectious, endocrine, metabolic, neurological, cardiovascular, hematological, cardiopulmonary, respiratory, musculoskeletal, renal, hepatological, gastrointestinal, genitourinary, ophthalmic, dermatological, and immune system related diseases and disorders; medicinal preparations, namely, for oncological, viral, infectious, endocrine, metabolic, neurological, cardiovascular, hematological, cardiopulmonary, respiratory, musculoskeletal, renal, hepatological, gastrointestinal, genitourinary, ophthalmic, dermatological, and immune system related diseases and disorders; living cells for manufacturing monoclonal antibodies used for medical purposes; cell lines for manufacturing monoclonal antibodies used for medical purposes; living cells for manufacturing monoclonal antibodies used for veterinary purposes; cell lines for manufacturing monoclonal antibodies used for veterinary purposes; biological tissue cultures for medical purposes, namely, for cultivating living cells or cell lines used for manufacturing monoclonal antibodies; dietary supplements for humans; nutritional supplements; dietary supplements for animals; dietetic foods, namely, protein adapted for medical purposes; dietetic beverages, namely, protein-based ready to drink beverages adapted for medical purposes; food for babies; powdered milk for babies; lacteal flour for babies; surgical implants comprised of living tissues; biological implants, namely, a vital processed human or animal connective tissue; disinfectants for hygiene purposes; sanitary sterilising preparations; biocides; preparations for destroying vermin ]
• CC0000: The color(s) blue and white is/are claimed as a feature of the mark.
• GS0421: Research, product development and quality control services in the field of proteins, antibodies, microorganisms and cells, and consultancy relating thereto; research and development services in the field of antibody technology; biomedical research services; [ design and development of medical technology; research and development in the field of biotechnology; ] pharmaceutical research and development [ ; conducting clinical trials for others in the field of pharmaceutical products; clinical trials for others; technical project studies in the field of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products; technical research in the field of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products; technical project planning in the field of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products; research and development of new products for others; design and development of computer software for use with medical technology; software design and development; providing temporary use of non-downloadable business software; rental of computer software; cloud computing featuring software used for development of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products ]

Case File Event Statements

• 11/12/2023 - a year ago

  47 - PARTIAL INVALIDATION PROCESSED BY THE IB Type: INNP

• 10/11/2023 - a year ago

  46 - PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB Type: INPS

• 10/11/2023 - a year ago

  45 - INVALIDATION PROCESSED Type: INPC

• 10/6/2023 - a year ago

  44 - PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED Type: INPR

• 2/6/2023 - a year ago

  43 - NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED Type: NA71

• 2/6/2023 - a year ago

  42 - REGISTERED-SEC.71 ACCEPTED Type: 71AG

• 2/3/2023 - a year ago

  41 - CASE ASSIGNED TO POST REGISTRATION PARALEGAL Type: APRE

• 1/29/2023 - a year ago

  40 - CASE ASSIGNED TO POST REGISTRATION PARALEGAL Type: APRE

• 1/19/2023 - a year ago

  39 - TEAS SECTION 71 RECEIVED Type: ES71

• 1/24/2022 - 2 years ago

  38 - COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED Type: REM3

• 8/4/2017 - 7 years ago

  37 - NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB Type: OPNX

• 5/12/2017 - 7 years ago

  36 - FINAL DECISION TRANSACTION PROCESSED BY IB Type: FINO

• 4/25/2017 - 7 years ago

  35 - FINAL DISPOSITION NOTICE SENT TO IB Type: FICS

• 4/25/2017 - 7 years ago

  34 - FINAL DISPOSITION PROCESSED Type: FIMP

• 4/24/2017 - 7 years ago

  33 - FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB Type: FICR

• 1/24/2017 - 7 years ago

  32 - REGISTERED-PRINCIPAL REGISTER Type: R.PR

• 1/6/2017 - 7 years ago

  31 - NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB Type: OPNX

• 1/4/2017 - 7 years ago

  30 - NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB Type: OPNS

• 1/4/2017 - 7 years ago

  29 - NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB Type: OPNR

• 11/8/2016 - 8 years ago

  28 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB

• 11/8/2016 - 8 years ago

  27 - PUBLISHED FOR OPPOSITION Type: PUBO

• 10/19/2016 - 8 years ago

  26 - NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB Type: OPNS

• 10/19/2016 - 8 years ago

  25 - NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB Type: OP2R

• 10/19/2016 - 8 years ago

  24 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP

• 10/3/2016 - 8 years ago

  23 - LAW OFFICE PUBLICATION REVIEW COMPLETED Type: PREV

• 9/24/2016 - 8 years ago

  22 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA

• 9/20/2016 - 8 years ago

  21 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME

• 9/19/2016 - 8 years ago

  20 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA

• 9/19/2016 - 8 years ago

  19 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA

• 3/17/2016 - 8 years ago

  18 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN

• 3/17/2016 - 8 years ago

  17 - NON-FINAL ACTION E-MAILED Type: GNRT

• 3/17/2016 - 8 years ago

  16 - NON-FINAL ACTION WRITTEN Type: CNRT

• 2/25/2016 - 8 years ago

  15 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME

• 2/25/2016 - 8 years ago

  14 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA

• 2/19/2016 - 8 years ago

  13 - ASSIGNED TO LIE Type: ALIE

• 2/15/2016 - 8 years ago

  12 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA

• 2/15/2016 - 8 years ago

  11 - ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Type: ARAA

• 2/15/2016 - 8 years ago

  10 - TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Type: REAP

• 9/4/2015 - 9 years ago

  9 - REFUSAL PROCESSED BY IB Type: RFNT

• 8/14/2015 - 9 years ago

  8 - NON-FINAL ACTION MAILED - REFUSAL SENT TO IB Type: RFCS

• 8/14/2015 - 9 years ago

  7 - REFUSAL PROCESSED BY MPU Type: RFRR

• 8/14/2015 - 9 years ago

  6 - NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW Type: RFCR

• 8/13/2015 - 9 years ago

  5 - NON-FINAL ACTION WRITTEN Type: CNRT

• 8/11/2015 - 9 years ago

  4 - APPLICATION FILING RECEIPT MAILED Type: MAFR

• 8/8/2015 - 9 years ago

  3 - ASSIGNED TO EXAMINER Type: DOCK

• 8/6/2015 - 9 years ago

  2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS

• 7/30/2015 - 9 years ago

  1 - SN ASSIGNED FOR SECT 66A APPL FROM IB Type: REPR